20,000 Shares in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Bought by Simplify Asset Management Inc.

Simplify Asset Management Inc. bought a new stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 20,000 shares of the company’s stock, valued at approximately $428,000. Simplify Asset Management Inc. owned about 0.13% of Jasper Therapeutics at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Samsara BioCapital LLC boosted its stake in Jasper Therapeutics by 11.4% in the third quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock valued at $10,997,000 after acquiring an additional 59,642 shares in the last quarter. Braidwell LP acquired a new position in shares of Jasper Therapeutics during the third quarter valued at about $9,091,000. Ally Bridge Group NY LLC grew its position in Jasper Therapeutics by 82.7% during the 3rd quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock worth $7,514,000 after purchasing an additional 180,852 shares during the last quarter. State Street Corp raised its holdings in shares of Jasper Therapeutics by 12.3% in the third quarter. State Street Corp now owns 214,883 shares of the company’s stock worth $4,042,000 after buying an additional 23,564 shares during the last quarter. Finally, FMR LLC acquired a new stake in shares of Jasper Therapeutics during the third quarter worth $722,000. 79.85% of the stock is currently owned by institutional investors.

Jasper Therapeutics Stock Down 1.9 %

Jasper Therapeutics stock opened at $5.21 on Friday. The company has a fifty day simple moving average of $5.79 and a 200-day simple moving average of $15.27. The firm has a market capitalization of $78.26 million, a price-to-earnings ratio of -1.10 and a beta of 2.23. Jasper Therapeutics, Inc. has a 52-week low of $4.55 and a 52-week high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings data on Thursday, February 27th. The company reported ($1.62) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.35). On average, research analysts anticipate that Jasper Therapeutics, Inc. will post -4.47 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Royal Bank of Canada reduced their price objective on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research note on Thursday, January 9th. JMP Securities reissued a “market outperform” rating and set a $70.00 price target on shares of Jasper Therapeutics in a report on Monday, January 6th. UBS Group initiated coverage on shares of Jasper Therapeutics in a report on Thursday, February 13th. They issued a “buy” rating and a $38.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Jasper Therapeutics in a research note on Tuesday, March 11th. Finally, BMO Capital Markets began coverage on Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 target price on the stock. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Jasper Therapeutics currently has an average rating of “Buy” and an average target price of $62.50.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.